Ferring Pharmaceuticals Ltd

The Courtyard, Waterside Drive, Langley, Berkshire, SL3 6EZ
Telephone: +44 (0)1753 214 800
Fax: +44 (0)1753 214 802
WWW: http://www.ferring.co.uk
Medical Information Direct Line: +44 (0)1753 214 845
Medical Information e-mail: medical@ferring.com
Medical Information Fax: +44 (0)1753 214 801
Summary of Product Characteristics last updated on the eMC: 15/09/2009
SPC Zomacton 4mg Injection

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 15/09/2009 and displayed until Current
Reasons for adding or updating:
  • Change to section 6. 3 - Shelf Life
  • Change to section 6. 5 - Nature and Contents of Container
Date of revision of text on the SPC:   06-Apr-2009
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

section 6.3 - Shelf life extended to 36 months.

section 6.5 - To replace the current CE marked syringe, used for reconstitution, with a new CE marked syringe, (the plunger material changed from ployethylene to polypropylene).
Updated on 25/10/2007 and displayed until 15/09/2009
Reasons for adding or updating:
  • Change to section 1 -Name of the Medicinal product
Date of revision of text on the SPC:   08/2006
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 1 - The full porduct name should be "Zomacton 4mg, powder and solvent for solution for injection ".
Updated on 17/07/2007 and displayed until 25/10/2007
Reasons for adding or updating:
  • Change to section 1 -Name of the Medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 4.8 - Undesirable Effects
  • Change to section 6. 3 - Shelf Life
  • Change to section 6. 4 - Special Precautions for Storage
  • Change to section 6. 6 - Instructions for use, handling and disposal
Date of revision of text on the SPC:   09/2006
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

The following SPC sections have been updated;
 
1. Name of product
2. Qualitative & Quantit.
3. Pharmaceutical form
4.2 Posology and method of administration
4.4 Special warnings
4.6 Pregnancy & lactation
4.8 Undesirable effects
6.3 Shelf life
6.4 Special precautions
6.6 Instruction for use
Updated on 09/02/2006 and displayed until 17/07/2007
Reasons for adding or updating:
  • Change to section 4.3 - Contra-indications
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 6.1 - List of Excipients
  • Change to section 10 (date of (partial) revision of the text
Updated on 19/08/2004 and displayed until 09/02/2006
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 26/11/2002 and displayed until 19/08/2004
Reasons for adding or updating:
  • Change to section 4.3 - Contra-indications
Updated on 28/08/2002 and displayed until 26/11/2002
Reasons for adding or updating:
  • New SPC for eMC ie an SPC for an existing product, but one that is new for the eMC

Active Ingredients/Generics

 
   somatropin


© 2010 Datapharm Communications Ltd

Go to www.medicines.org.uk